Physician profile
Robert K Partrige
NPI 1265540603
$1,762.06
in general payments reported to CMS, 2019-2025
25 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.28 · 2020: $93.33 · 2021: $224 · 2022: $356 · 2023: $235 · 2024: $360 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.17 | 2021-2025 | |
| Lilly USA, LLC | $222.84 | 2021-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $171.52 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $142.30 | 2025 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $98.33 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.63 | 2021-2022 | |
| Glaxosmithkline, LLC. | $68.86 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.77 | 2022-2025 | Caplyta |
| Pfizer INC. | $62.86 | 2021-2024 | |
| Allergan, INC. | $60.48 | 2020 | |
| Amgen INC. | $49.04 | 2024-2025 | Prolia, Evenity, Otezla |
| Merck Sharp & Dohme LLC | $46.44 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.29 | 2022 | |
| Shionogi INC | $32.36 | 2019 | |
| Smith+Nephew, INC. | $30.22 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.28 | 2023 | Ofev |
| Medtronic, INC. | $26.72 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.21 | 2025 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $22.36 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.87 | 2024 | Xifaxan |
| Grt US Holding, INC. | $19.26 | 2021 | |
| Amarin Pharma, INC. | $18.50 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.86 | 2023 | Rexulti |
| Adlon Therapeutics L.P. | $11.89 | 2021 | |
| Genentech USA, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Partrige listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.